homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

August 12, 2021

Visus Therapeutics

Visus Therapeutics, a clinical-stage pharmaceutical company focused on developing ophthalmic therapies to improve vision for people around the world, announced the closing of $20 million in preferred stock financing, led by LSP in Amsterdam, along with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation — JJDC, and other inside investors in the company. In conjunction with this financing, John de Koning, Ph.D., a general partner at LSP, has joined the company's board of directors. For more than a decade, de Koning was the organizer of BioCapital Europe, an annual life sciences investment conference. The company recently announced that it will be hosting its debut Capital Markets Day on Aug. 31 in New York City and virtually for investors and media. Visus Therapeutics has offices in Seattle and Orange County, California.




Email or user name:
Password:
 
Forgot password? Click here.